Payment overview · 2025
General Payments
$197.85
9 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Shane Scott, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW ALBANY, MS · NPI 1275535551
Verified facts
What the public records show
CMS Open Payments records show Michael Shane Scott, D.O. received $197.85 in general payments during 2025 across 9 reported records.
GE HEALTHCARE accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $62.86 | 31.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.56 | 26.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.85 | 10.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.65 | 9.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.79 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 7.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.97 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.85 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $51.56 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 48 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 37 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 58 |
| Furosemide | Furosemide | 194 | 62 |
| Omeprazole | Omeprazole | 194 | 62 |
| Gabapentin | Gabapentin | 188 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 185 | 59 |
| Carvedilol | Carvedilol | 169 | 50 |
| Potassium Chloride | Potassium Chloride | 166 | 52 |
| Meloxicam | Meloxicam | 162 | 46 |
| Famotidine | Famotidine | 142 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 36 |
| Metformin Hcl | Metformin Hcl | 137 | 41 |
| Lisinopril | Lisinopril | 133 | 46 |
| Losartan Potassium | Losartan Potassium | 133 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 37 |
| Ezetimibe | Ezetimibe | 124 | 34 |
| Clonazepam | Clonazepam | 120 | 28 |
| Trazodone Hcl | Trazodone Hcl | 115 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 28 |
| Alendronate Sodium | Alendronate Sodium | 92 | 26 |
| Montelukast Sodium | Montelukast Sodium | 92 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 18 |
| Spironolactone | Spironolactone | 77 | 30 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 19 |
| Celecoxib | Celecoxib | 64 | 17 |
| Sertraline Hcl | Sertraline Hcl | 62 | 22 |
| Prednisone | Prednisone | 58 | 34 |
| Ozempic | Semaglutide | 57 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 24 |
| Jardiance | Empagliflozin | 56 | 16 |
| Fenofibrate | Fenofibrate | 53 | 17 |
| Allopurinol | Allopurinol | 51 | 16 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 45 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 40 |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Finasteride | Finasteride | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Eliquis | Apixaban | 36 | 12 |
| Estradiol | Estradiol | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 15 |
| Simvastatin | Simvastatin | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 14 |
| Baclofen | Baclofen | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 12 |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.85 · 9 records | GE HEALTHCARE | ABRYSVO, AREXVY, BEXSERO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, GARDASIL 9, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, VAXNEUVANCE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error